NCT05502250
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05502250
Title Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (HOVON164HL)
Acronym HOVON164HL
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Stichting Hemato-Oncologie voor Volwassenen Nederland
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD | DNK | BEL

Facility Status City State Zip Country Details
BE-Bruxelles-STLUC Brussels Belgium Details
DK-Aarhus N-AUH Aarhus Denmark Details
DK-Copenhagen-RIGSHOSPITALET Copenhagen Denmark Details
DK-Odense-OUH Odense Denmark Details
NL-Amersfoort-MEANDERMC Amersfoort Netherlands Details
NL-Amsterdam-AMC Amsterdam Netherlands Details
NL-Arnhem-RIJNSTATE Arnhem Netherlands Details
NL-Eindhoven-MAXIMAMC Eindhoven Netherlands Details
NL-Goes-ADRZ Goes Netherlands Details
NL-Groningen-UMCG Groningen Netherlands Details
NL-Hoofddorp-SPAARNEGASTHUIS Hoofddorp Netherlands Details
NL-Leeuwarden-MCL Leeuwarden Netherlands Details
NL-Maastricht-MUMC Maastricht Netherlands Details
NL-Rotterdam-ERASMUSMC Rotterdam Netherlands Details
NL-Den Haag-HAGA The Hague Netherlands Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field